DOI · e01.org

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone

Liancheng Fan, Chenfei Chi, Sanwei Guo, Yanqing Wang, Wen Cai, Xiaoguang Shao, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Hongyang Qian, Shaowei Xie, Rui Wang, Lixin Zhou, Baijun Dong, Wei Xue · Journal of Cancer · 2017

  • DOI 10.7150/jca.21134
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2017

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2017

Abstract

Objective To determine the prognostic utility of serum pre-albumin in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (AA).Patients and Methods 112 chemotherapy pretreated or chemotherapy-naive patients were scheduled for systemic treatment with AA.Serum pre-albumin levels were measured before and after 3 months of AA treatment.Univariate and multivariate analyses were performed to determine prognostic factors that were associated with PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS).The Harrell concordance index with variables only or combined pre-albumin data were used to evaluate the prognostic accuracy.

ResultsThe group of patients with baseline pre-albumin value ≥20mg/dL had a longer OS, PSA-PFS, rPFS than those with pre-albumin value <20mg/dL.Based on the values of pre-albumin before and after 3 months of AA treatment, we divided these patients into 4 groups: high-high, high-low, low-high and low-low group.High-high group showed a significantly better OS, PSA-PFS, rPFS than other 3 groups.In multivariate analysis, low pre-albumin level remained significant predictors of OS (HR, 13.2; P<0.001), rPFS (HR, 3.7; P=0.003) and PSA-PFS (HR, 8.7; P<0.001).The estimated c-index of the multivariate model for OS increased from 0.814 without pre-albumin to 0.845 when pre-albumin added.Conclusion Low pretreatment serum pre-albumin is a negative independent prognosticator of survival outcomes in mCRPC treated with AA and also increases the accuracy of established prognostic model.Serial pre-albumin evaluation might help clinicians guide clinical treatment of mCRPC patients.

Open the resolved locator · 10.7150/jca.21134

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:12 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v08p3448.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.